Easotic Dailymed
Prescription Animal - Aminoglycoside Antibacterial
- Virbac AH, Inc.
Generic: hydrocortisone aceponate, miconazole nitrate, and gentamicin sulfate is used for the treatment of Bone Diseases, Infectious Central Nervous System Infections Endocarditis Endocarditis, Bacterial Escherichia coli Infections Hypersensitivity Klebsiella Infections Proteus Infections Pseudomonas Infections Respiratory Tract Infections Staphylococcal Infections Peritonitis, Tuberculous Urinary Tract Infections Eye Infections, Bacterial Serratia Infections Skin Diseases, Bacterial Soft Tissue Infections Sepsis Adrenal Insufficiency Adrenal Hyperplasia, Congenital Colitis, Ulcerative Dermatitis, Contact Dermatomycoses Facial Dermatoses Foot Dermatoses Hand Dermatoses Hemorrhoids Inflammation Leg Dermatoses Pruritus Ani Rheumatic Diseases Scalp Dermatoses Shock Skin Diseases, Parasitic Status Asthmaticus Tuberculosis, Cutaneous Skin Diseases, Viral Aspergillosis Candidiasis, Cutaneous Candidiasis, Vulvovaginal Tinea Pedis Tinea Versicolor
Go PRO for all pill images
(hydrocortisone aceponate, miconazole nitrate, gentamicin sulfate)Otic Suspension for DogsAnti-inflammatory, antifungal, and antibacterial
Rx
For Otic Use in Dogs Only
Caution
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Description
EASOTIC® Otic Suspension contains 1.11 mg/mL hydrocortisone aceponate, 17.4 mg/mL miconazole nitrate and 1.5 mg/mL gentamicin (as sulfate). The inactive ingredient is a semi-liquid petroleum jelly.
Indications
EASOTIC Otic Suspension is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).
Dosage And Adminstration
Verify that the tympanic membrane is intact. Shake well before each use.
Priming the canister: Prior to the first use of the dosing container, press firmly on the pump several times until the product fills the nozzle (canula tip) with a full dose of product.
Carefully insert the canula into the affected external ear canal(s) and apply 1 mL (a single pump) of Otic Suspension once per day for 5 days. Wash hands after usage.
Contraindications
Do not use in dogs with known tympanic membrane perforation.
EASOTIC Otic Suspension is contraindicated in dogs with known or suspected hypersensitivity to corticosteroids, imidazole antifungals, or aminoglycoside antibiotics.
Warnings
Human Warnings: Not for use in humans. Keep this and all drugs out of reach of children. In case of accidental skin contact, wash area thoroughly with water. Avoid contact with eyes.
Humans with known or suspected hypersensitivity to hydrocortisone, aminoglycoside antibiotics, or azole antifungals should not handle thisproduct.
In case of accidental ingestion by humans, contact a physician immediately. Physicians may contact a Poison Control Center for advice concerning cases of ingestion by humans.
Animal Warnings: As a class, aminoglycoside antibiotics are associated with ototoxicty, vestibular dysfunction and renal toxicity. The use of EASOTIC Otic Suspension in a dog with a damaged tympanic membrane can result in damage to the structures of the ear associated with hearingand balance or in transmission of the infection to the middle or inner ear. Immediately discontinue use of EASOTIC Otic Suspension if hearing loss or signs of vestibular dysfunction are observed during treatment (see ADVERSE REACTIONS).
Precautions
Do not administer orally.
Concurrent administration of potentially ototoxic drugs should be avoided.
Use with caution in dogs with impaired hepatic or renal function (see ANIMAL SAFETY).
Long-term use of topical otic corticosteroids has been associated with adrenocortical suppression and iatrogenic hyperadrenocorticism in dogs (see ANIMAL SAFETY).
The safe use of EASOTIC Otic Suspension in dogs used for breeding purposes, during pregnancy, or in lactating bitches, has not beenÂevaluated.
Adverse Reactions
In a field study conducted in the United States (see EFFECTIVENESS), there were no adverse reactions reported in 145 dogs administered EASOTIC Otic Supsension.
In foreign market experience, reports of hearing loss and application site erythema have been received. In most reported cases, the hearing loss and erythema were transient and resolved with discontinuation of EASOTIC® suspension.
To report suspected adverse drug events, contact Virbac AH, Inc at 1-800-338-3659 or the FDA at 1-888-FDA-VETS or www.fda.gov/reportanimalae.
For technical assistance or to obtain a Safety Data Sheet, call Virbac at 800-338-3659 or visit us at us.virbac.com.
Pharmacology
Hydrocortisone aceponate is a glucocorticoid with anti-inflammatory effects. Miconazole nitrate is an imidazole antifungal. Gentamicin sulfate is an aminoglycoside antibiotic.Â
In the target animal safety study, hydrocortisone aceponate, miconazole and gentamicin were shown to be systemically absorbed from the ears of healthy dogs (see ANIMAL SAFETY); increased systemic absorption may be observed in inflamed ears.
Microbiology
The compatibility and additive effect of each of the components in EASOTIC® Otic Suspension was demonstrated in a component effectiveness and non-interference study. An in vitro study of organisms collected from clinical cases of otitis externa in dogs and from dogs enrolled in the clinical effectiveness study for EASOTIC Otic Suspension determined that miconazole nitrate and gentamicin sulfate inhibit the growth of bacteria and yeast commonly associated with otitis externa in dogs. No consistent synergistic or antagonistic effect of the two antimicrobials was demonstrated. The addition of hydrocortisone aceponate to the combination did not impair antimicrobial activity to any clinically-significant extent.
In a field study (see EFFECTIVENESS), the minimum of 10 isolates from successfully treated cases was met for S. pseudintermedius and M. pachydermatis.
Effectiveness
The effectiveness of this drug was evaluated in 157 dogs with otitis externa. The study was a double-masked field study with a placebo control. One hundred and four dogs were treated with EASOTIC Otic Suspension and 53 dogs were treated with the placebo control. Treatment was administered once daily for 5 consecutive days to the affected ear(s). The dogs were evaluated at 4 different intervals over the course of 1 month to determine response to therapy. The 6 clinical signs evaluated were: malodor, aural discharge, pruritus, erythema, swelling and pain. The individual clinical scores were assigned based on the severity of each sign. Success was based on clinical improvement at Day 28 ±2 days. The success rates of the 2 groups were significantly different (p=0.0179); 68.5% of dogs administered EASOTIC Otic Suspension were successfully treated, compared to 21.8% of the dogs in the placebo control group.
Animal Safety
In the target animal safety study, EASOTIC Otic Suspension was administered at 0X, 1X, 3X and 5X the recommended dose for 15 consecutive days (3 times the recommended treatment duration) in laboratory Beagles, with 8 dogs per group. Hypersensitivity reactions in the external ear canal and inner pinnae were seen in all EASOTIC Otic Suspension groups and included mild to severe aural erythema (3X group), papules and ulceration (1X and 5X groups), otitis externa (3X and 5X groups), and otitis media (5X group). Renal tubular crystals were present in the cortex and medulla (0X, 1X, 3X, and 5X groups) and mild renal tubular basophilia and atrophy were present in one 5X group dog. Baseline cortisol values and the cortisol response to ACTH stimulation were lower in treated dogs compared to the control dogs. The ACTH stimulation test results are consistent with systemic absorption of topical corticosteroids causing suppression of the hypothalamic-pituitary-adrenal axis. Dogs in the 3X and 5X groups demonstrated elevations in AST and ALP, while dogs in the 1X, 3X, and 5X groups had elevated cholesterol, total protein, and albuminlevels. Dogs in the 3X and 5X groups also had higher liver weights and greater food consumption.
Storage Information
Store at temperatures between 20o C-25o C (68o F-77o F), with excursions permitted between 15o C-30o C (59o F-86o F).
How Supplied
EASOTIC Otic Suspension is supplied in a polyethylene canister, with a soft applicator canula.
Each canister contains ten 1 mL doses.
Made in the U.S.A.
Distributed by:Virbac AH, Inc.P.O. Box 162059Fort Worth, TX 76161 USA
Approved by FDA under NADA # 141-330Revision Date 04/2020
© 2020 Virbac Corporation. All Rights Reserved. EASOTIC is a registred trademark of Virbac S.A. 302076-04
Package Label.principal Display Panel
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
